The process of staging squamous cell carcinoma is a vital part of clinical management in the United Kingdom, as it allows doctors to determine the exact extent of the cancer and plan the most effective treatment. Staging is usually reserved for larger or more aggressive lesions that carry a higher risk of growing deeply or spreading to other areas of the body. For the majority of small and early-stage tumours, a simple clinical examination and a biopsy are often sufficient to proceed directly to treatment. When staging is necessary, it provides a universal language for medical teams to discuss the severity of the condition and ensures that every patient receives a level of care that is tailored to their specific diagnosis.
What We’ll Discuss in This Article
- The application of the TNM8 staging system in British healthcare
- The difference between clinical and pathological staging
- Categorisation from stage 0 through to stage 4
- Factors such as tumour size and depth of invasion
- The assessment of regional lymph nodes for signs of spread
- Diagnostic imaging tests used to confirm the stage of the cancer
- How staging information influences the final treatment plan
The TNM8 staging system in the United Kingdom
The primary method used for staging squamous cell carcinoma in the UK is the 8th edition of the TNM system, which was implemented nationally in 2018. This system is managed by the Union for International Cancer Control and provides a standardised framework for assessing the primary tumour, the involvement of regional lymph nodes, and the presence of distant metastases. By using this system, multidisciplinary teams in the NHS can categorise a cancer based on its physical and biological characteristics, which helps in predicting the likely outcome and selecting the most appropriate interventions.
The National Health Service explains that doctors use the TNM system to stage your cancer, which stands for tumour, node, and metastasis, to describe how far the cancer has grown or spread. The T category describes the size and depth of the primary growth, the N category indicates whether the cancer has reached nearby lymph nodes, and the M category identifies if the cancer has spread to distant organs such as the lungs. This structured approach ensures that high-risk cases are identified early and managed with the necessary level of clinical urgency. For patients, understanding their TNM stage can provide clarity on why certain treatments or follow-up protocols have been recommended by their specialist.
Clinical and pathological staging stages
In the UK, staging is divided into two distinct phases: clinical and pathological. Clinical staging is performed before any treatment begins and is based on a physical examination of the skin, an assessment of the nearby lymph glands, and any initial imaging scans. This provides an early estimate of the extent of the disease. Pathological staging occurs after the tumour has been surgically removed and examined under a microscope by a consultant pathologist. This stage is often more accurate because it allows for a precise measurement of the tumour thickness and a detailed look at the cell structure.
The pathological stage is considered the gold standard for finalising the treatment plan. NICE clinical guidelines recommend that all squamous cell carcinomas should be assessed for high-risk features such as depth and nerve involvement to determine if more intensive staging or treatment is required. If the laboratory report shows that the cancer is more advanced than initially thought, the medical team may upgrade the stage and recommend additional measures such as radiotherapy or further scans. This two-step process ensures that the clinical team has the most complete picture possible before deciding on the next steps in a patient’s care journey.
Stage 0 and the early classifications
Stage 0 is the earliest possible classification and is often referred to as carcinoma in situ or Bowen’s disease. In this stage, the cancerous cells are located only in the very top layer of the skin, the epidermis, and have not yet begun to grow into the deeper dermal layers. Because the cells are contained, the risk of spread is virtually zero at this point. Identifying an SCC at stage 0 is an excellent outcome, as it can usually be cured with very simple treatments such as specialised creams or minor surgical procedures.
Stage 1 describes a small, invasive tumour that is two centimetres or less in its widest dimension. These lesions have started to grow into the deeper layers of the skin but are still considered low risk because they have not yet reached any lymph nodes or distant sites. Stage 2 includes larger tumours that are between two and four centimetres across. While these are still localised to the skin, their increased size means they require more careful management to ensure they are fully removed with a healthy margin of tissue. In both stages 1 and 2, the primary focus is on achieving a local cure and preventing the cancer from progressing further.
Advanced staging from stage 3 to stage 4
A squamous cell carcinoma is classified as stage 3 when it has become significantly larger or has shown signs of spreading to the regional lymph nodes. This stage can include tumours that are larger than four centimetres in diameter or those that have grown deeply into the underlying fat, muscle, or around the nerves. It also includes cases where a single, small lymph node on the same side of the body as the tumour is involved. Stage 3 tumours are considered locally advanced and often require a combination of surgery and radiotherapy to ensure the area is clear of cancer.
Stage 4 is the most advanced classification and indicates that the cancer has spread to distant parts of the body, such as the lungs, liver, or bones, or has invaded the bone at the original site. This is a very rare occurrence for squamous cell carcinoma but requires intensive management by a team of oncology specialists. In these cases, the focus may shift toward systemic treatments like immunotherapy or chemotherapy that work throughout the body to target cancer cells wherever they have travelled. The goal of staging at this level is to understand the full burden of the disease and to provide the best possible support and treatment to manage the condition.
Diagnostic imaging used for staging
For tumours that are suspected of being advanced or high-risk, UK clinicians will use specialised imaging tests to assist in the staging process. An ultrasound scan is often the first tool used to examine the regional lymph nodes in the neck, armpit, or groin. Ultrasound is a quick and non-invasive way to look for any nodes that appear enlarged or have an abnormal internal structure. If a suspicious node is found, a small needle may be used to take a sample of cells for laboratory testing.
In more complex cases, a CT or MRI scan may be required to provide a more detailed view. A CT scan is excellent for looking at the chest and abdomen to check for distant spread, while an MRI scan is often preferred for looking at tumours on the head and neck as it provides superior images of soft tissues and nerves. These scans allow the medical team to see what is happening beneath the surface and are essential for accurate T and N categorisation in the TNM8 system. By using these technologies, the NHS ensures that the staging of squamous cell carcinoma is as precise as possible, leading to better outcomes and more informed patient care.
High risk factors and their impact on staging
Several clinical factors can influence the final stage and the perceived risk of a squamous cell carcinoma. The depth of the tumour, typically measured in millimetres from the surface, is a vital indicator; tumours deeper than six millimetres are generally viewed with more concern. The degree of differentiation, which describes how much the cancer cells look like normal skin cells, is also considered. Poorly differentiated tumours are those where the cells look very abnormal, and these are statistically more likely to grow quickly and spread.
The presence of perineural invasion, where cancer cells are found growing along the path of a nerve, is another high-risk feature that can impact the staging and treatment plan. This finding suggests the cancer has a more invasive potential and may require wider surgical margins or adjuvant radiotherapy. In the UK, the multidisciplinary team reviews all of these pathological details alongside the tumour size to create a comprehensive risk profile. This thorough evaluation ensures that no aspect of the cancer’s behaviour is overlooked, providing a robust foundation for successful long-term management.
Conclusion
Staging squamous cell carcinoma in the UK follows the TNM8 system, which categorises the cancer based on the size of the tumour, lymph node involvement, and distant spread. While early-stage lesions are often managed simply, advanced stages require detailed imaging and multidisciplinary review to ensure a complete cure. This structured process provides the clinical certainty needed for both the medical team and the patient. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
What is the difference between stage 0 and stage 1 SCC?
Stage 0 is contained within the top layer of the skin, whereas stage 1 has begun to grow into the deeper dermal layers but remains small and localised.
Do all SCC patients in the UK need a CT scan?
No, scans are usually only necessary for high-risk tumours, very large lesions, or if there is a clinical suspicion that the cancer has spread to the lymph nodes.
What does it mean if my SCC is poorly differentiated?
This describes the appearance of the cells under a microscope and suggests the cancer may be more aggressive, which may influence its stage and treatment.
Can my stage change after I have surgery?
Yes, the pathological stage determined after surgery is often more accurate than the initial clinical stage and may lead to adjustments in your care plan.
Is stage 4 SCC common in the UK?
Fortunately, stage 4 is very rare, as most squamous cell carcinomas are identified and successfully treated while they are still localised to the skin.
What is perineural invasion in a staging report?
This is when cancer cells are found around a nerve, which is a high-risk finding that indicates a greater potential for the cancer to spread locally.
How long does it take to get my staging results?
While clinical staging can be done quickly, the final pathological stage usually takes one to two weeks while the laboratory processes the tissue sample.
Authority Snapshot (E-E-A-T)
This article is designed to provide clear and factual information regarding skin health for the general public. The content is written by the Medical Content Team and has been reviewed by Dr. Stefan Petrov. He is a UK-trained physician with an MBBS and postgraduate certifications including Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and the UK Medical Licensing Assessment (PLAB 1 & 2). He has hands-on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient-focused health content and teaching clinical skills to junior doctors.
